ஒரையந் குழு இடைக்கால அறிக்கை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Strong first quarter as exceptional circumstances continue
“In the early part of 2021, the exceptional circumstances brought on by the COVID-19 pandemic are still prevailing. For Orion, this means continuing to focus on looking after the health and safety of our employees and ensuring production continuity, product availability and patient safety in ongoing clinical trials.
In January–March 2021, Orion s net sales were EUR 269 (280) million and operating profit EUR 75 (84) million. As anticipated, they fell below the robust comparative period when the peak in demand for pharmaceuticals caused by the COVID-19 pandemic gave a boost to sales and profits. The Specialty Products unit had a good quarter even though due to the coronavirus pandemic and related restrictions implemented in various countries, the prevalence of seasonal illnesses such as the common flu has been lower than normal, and there has been a decline in non-critical procedures and medical appointments. Th ....

Eteläuomen Läi , United States , United Kingdom , Tuukka Hirvonen , Jari Karlson , Timo Lappalainen , Board Of Directors Orion Corporation , Orion Group Interim , Animal Health , Orion Corporation , Orion Group Interim Report , Groupinterim Report , Interim Report , Specialty Products , Year Financial Report January June , Report January September , Investor Relations , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , ஜரி கார்ல்சன் , பலகை ஆஃப் இயக்குநர்கள் ஒரையந் நிறுவனம் , ஒரையந் குழு இடைக்கால , விலங்கு ஆரோக்கியம் , ஒரையந் நிறுவனம் , ஒரையந் குழு இடைக்கால அறிக்கை , இடைக்கால அறிக்கை ,